Last update 01 Nov 2024

FGFR1 x FLT3 x Bcr-Abl T315I

Basic Info

Related Targets
FGFR1FLT3Bcr-Abl T315I

Related

1
Drugs associated with FGFR1 x FLT3 x Bcr-Abl T315I
KW-2449
Target
Bcr-Abl T315I x FGFR1 x FLT3
Mechanism
Bcr-Abl T315I inhibitors [+2]
Active Org.-
Originator Org.
Kyowa Hakko Kirin Pharma, Inc.
Active Indication-
Inactive Indication
acute leukemia [+5]
Drug Highest PhaseDiscontinued
First Approval Ctry. / Loc.-
First Approval Date20 Jan 1800
2
Clinical Trials associated with FGFR1 x FLT3 x Bcr-Abl T315I
NCT00779480 / TerminatedPhase 1
Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Study of KW-2449 in Acute Myelogenous Leukemia
NCT00346632 / TerminatedPhase 1
Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of KW-2449 in Acute Leukemias (AML), Myelodysplastic Syndromes (MDS), and Chronic Myelogenous Leukemia (CML)
100 Clinical Results associated with FGFR1 x FLT3 x Bcr-Abl T315I
Login to view more data
100 Translational Medicine associated with FGFR1 x FLT3 x Bcr-Abl T315I
Login to view more data
0 Patents (Medical) associated with FGFR1 x FLT3 x Bcr-Abl T315I
Login to view more data

Analysis

Perform a panoramic analysis of this field.
login
or
view full example data
Perform a panoramic analysis of this field.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free